Virax Biolabs Group Limited (VRAX)

$0.63 -0.01 (-2.24%)
Market Cap 2.99M
Revenue (ttm) 10,000.00
Net Income (ttm) -6.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60,600.00%
Debt to Equity Ratio 0.01
Volume 1,538,000
Avg Vol 6,191,850
Day's Range N/A - N/A
Shares Out 4.34M
Stochastic %K 57%
Beta 1.67
Analysts Strong Sell
Price Target $3.00

Company Profile

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7788 7414
Address:
BioCity Glasgow, Bo’Ness Road Newhouse, Lanarkshire, United Kingdom
dhughes80
dhughes80 Dec. 5 at 6:48 PM
$VRAX ALERT!!! DON’T SELL FOR A LOSS!!!
0 · Reply
dhughes80
dhughes80 Dec. 5 at 6:46 PM
$VRAX ALERT!!! DO NOT SELL!!! Borrow rate dramatically increased within the last hour or so from 404% to over 1200%!!!! I don’t normally do comparisons BUT $SMX was at 950% all day during its run!!!!
1 · Reply
dhughes80
dhughes80 Dec. 5 at 6:41 PM
$VRAX Fam!!! Everyone keeps staring at the chart, but you’re missing the real story: the borrow rate just exploded to 1,205% from 404% just two hours ago!That’s not “high” — that’s shorts in full survival mode. At this level, brokers start force-returning shares, shorts bleed money every hour, and NEW short positions can’t even open. Liquidity is gone. The float is effectively LOCKED. This is exactly how the biggest micro-float squeezes start: low volume… controlled price action… shorts trapped… and then BOOM — one spark sets off a vertical move because they have no ammo left. VRAX reclaimed EMA, SMA, and VWAP, RSI reset clean, and we’ve got a tight consolidation base forming right under resistance. I’m not calling tops or bottoms — I’m calling conditions. And right now, the borrow dynamics alone are enough to create a face-ripping squeeze if volume spikes even a little. Shorts CANNOT hold 1,205% for long. Something has to break… and when it does, it’s explosive. Stay sharp. 🚀🔥
0 · Reply
Meksss
Meksss Dec. 5 at 3:18 PM
$VRAX Constant test of .64 should break .65z
0 · Reply
Meksss
Meksss Dec. 5 at 3:06 PM
$VRAX .65 clean brewk takes is to about $.77 and we hit that and we run to $1, maybe $1.2 ish who knows; send it.
0 · Reply
Perpar
Perpar Dec. 5 at 3:04 PM
$VRAX 1. Dollar
0 · Reply
Meksss
Meksss Dec. 5 at 3:03 PM
$VRAX Send it VRAX, send it.
1 · Reply
Meksss
Meksss Dec. 5 at 2:52 PM
$VRAX Why is this just stand still?
1 · Reply
The_Fifteen_Percent_Guy
The_Fifteen_Percent_Guy Dec. 5 at 2:23 PM
✏️ $KITT $SRFM $VRAX $BYND top watches on open today
0 · Reply
SonicPricey
SonicPricey Dec. 5 at 1:52 PM
Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $VRAX $YYAI $TGEN $AG Watchlist
0 · Reply
Latest News on VRAX
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Dec 4, 2025, 4:05 PM EST - 1 day ago

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Virax Biolabs Group Limited Announces $5 Million Private Placement

Dec 3, 2025, 1:53 PM EST - 2 days ago

Virax Biolabs Group Limited Announces $5 Million Private Placement

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Dec 3, 2025, 7:34 AM EST - 2 days ago

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Nov 3, 2025, 8:29 AM EST - 4 weeks ago

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Jul 29, 2025, 7:35 AM EDT - 4 months ago

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Jul 18, 2025, 4:15 PM EDT - 5 months ago

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Mar 31, 2025, 2:57 PM EDT - 8 months ago

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Mar 18, 2025, 7:30 AM EDT - 9 months ago

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Mar 13, 2025, 7:30 AM EDT - 9 months ago

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Mar 5, 2025, 7:30 AM EST - 9 months ago

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Feb 25, 2025, 7:00 AM EST - 10 months ago

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Jan 23, 2025, 3:35 PM EST - 11 months ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

COSM

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Jan 13, 2025, 9:20 AM EST - 11 months ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

COSM

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Dec 17, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Dec 10, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

COSM

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

COSM

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Virax Biolabs to Participate at 7th European Congress of Immunology

Aug 29, 2024, 9:03 AM EDT - 1 year ago

Virax Biolabs to Participate at 7th European Congress of Immunology

Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know

Aug 28, 2024, 2:18 PM EDT - 1 year ago

Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Aug 28, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Aug 23, 2024, 4:09 PM EDT - 1 year ago

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Aug 21, 2024, 9:30 PM EDT - 1 year ago

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

Aug 21, 2024, 10:20 AM EDT - 1 year ago

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

COSM

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Virax Biolabs to Participate at ESCMID Global 2024

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs to Participate at ESCMID Global 2024

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Dec 21, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation

Dec 14, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Sep 12, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Sep 1, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

Jul 18, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

May 4, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Apr 19, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 10, 2023, 5:17 PM EST - 2 years ago

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 8, 2023, 8:55 AM EST - 2 years ago

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Mar 7, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

Feb 7, 2023, 9:15 AM EST - 3 years ago

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

COSM

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

Feb 7, 2023, 8:30 AM EST - 3 years ago

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

COSM

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Feb 6, 2023, 4:05 PM EST - 3 years ago

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Jan 4, 2023, 7:30 AM EST - 3 years ago

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Dec 6, 2022, 7:30 AM EST - 3 years ago

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Nov 15, 2022, 7:30 AM EST - 3 years ago

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

Nov 8, 2022, 4:30 PM EST - 3 years ago

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

Virax Biolabs Group Limited Announces $3.8 Million Private Placement

Nov 4, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces $3.8 Million Private Placement

Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Oct 26, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

Sep 22, 2022, 8:07 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

COSM

dhughes80
dhughes80 Dec. 5 at 6:48 PM
$VRAX ALERT!!! DON’T SELL FOR A LOSS!!!
0 · Reply
dhughes80
dhughes80 Dec. 5 at 6:46 PM
$VRAX ALERT!!! DO NOT SELL!!! Borrow rate dramatically increased within the last hour or so from 404% to over 1200%!!!! I don’t normally do comparisons BUT $SMX was at 950% all day during its run!!!!
1 · Reply
dhughes80
dhughes80 Dec. 5 at 6:41 PM
$VRAX Fam!!! Everyone keeps staring at the chart, but you’re missing the real story: the borrow rate just exploded to 1,205% from 404% just two hours ago!That’s not “high” — that’s shorts in full survival mode. At this level, brokers start force-returning shares, shorts bleed money every hour, and NEW short positions can’t even open. Liquidity is gone. The float is effectively LOCKED. This is exactly how the biggest micro-float squeezes start: low volume… controlled price action… shorts trapped… and then BOOM — one spark sets off a vertical move because they have no ammo left. VRAX reclaimed EMA, SMA, and VWAP, RSI reset clean, and we’ve got a tight consolidation base forming right under resistance. I’m not calling tops or bottoms — I’m calling conditions. And right now, the borrow dynamics alone are enough to create a face-ripping squeeze if volume spikes even a little. Shorts CANNOT hold 1,205% for long. Something has to break… and when it does, it’s explosive. Stay sharp. 🚀🔥
0 · Reply
Meksss
Meksss Dec. 5 at 3:18 PM
$VRAX Constant test of .64 should break .65z
0 · Reply
Meksss
Meksss Dec. 5 at 3:06 PM
$VRAX .65 clean brewk takes is to about $.77 and we hit that and we run to $1, maybe $1.2 ish who knows; send it.
0 · Reply
Perpar
Perpar Dec. 5 at 3:04 PM
$VRAX 1. Dollar
0 · Reply
Meksss
Meksss Dec. 5 at 3:03 PM
$VRAX Send it VRAX, send it.
1 · Reply
Meksss
Meksss Dec. 5 at 2:52 PM
$VRAX Why is this just stand still?
1 · Reply
The_Fifteen_Percent_Guy
The_Fifteen_Percent_Guy Dec. 5 at 2:23 PM
✏️ $KITT $SRFM $VRAX $BYND top watches on open today
0 · Reply
SonicPricey
SonicPricey Dec. 5 at 1:52 PM
Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $VRAX $YYAI $TGEN $AG Watchlist
0 · Reply
Meksss
Meksss Dec. 5 at 1:29 PM
$VRAX Just needs a .65 break and we moon, they keep pinning it down.
0 · Reply
SonicPriced
SonicPriced Dec. 5 at 12:44 PM
Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $MSGY $VRAX $OUST $VERI Picks
0 · Reply
__MoonWatcherz
__MoonWatcherz Dec. 5 at 11:15 AM
That call was insane dude, Made my whole week! Made 7k$ profit :) Shout out to @ReversalFox for nailing that run last night! FOLLOW him, Amazing trader! Volume on $QTTB $XCUR $JFBR $VRAX now
0 · Reply
Nostardam2000
Nostardam2000 Dec. 5 at 11:12 AM
$VRAX whats happening now only 1 dollar premarket?
0 · Reply
StellyD
StellyD Dec. 5 at 10:27 AM
$VRAX let’s see what today holds us
0 · Reply
Joseph_86
Joseph_86 Dec. 5 at 9:50 AM
$VRAX optimum price target ?
0 · Reply
Perpar
Perpar Dec. 5 at 9:14 AM
$VRAX 🔥💣
0 · Reply
Swats20
Swats20 Dec. 5 at 5:04 AM
$VRAX price target?
1 · Reply
SadyK189
SadyK189 Dec. 5 at 2:56 AM
Top Stocks to watch tomorrow 2 / 2: $AKAN $XCUR $SUGP $VRAX $IXHL VRAX: Looking good on 4hours chart. Key support 0.53 - 0.57. Next key level to test is 0.78 - 0.83. Currently at 0.65. IXHL has held key support zone of 0.37 - 0.41 nicely so far. Next key level to test is 0.56 - 0.59. Currently at 0.47. AKAN: Good close of 4hours candle. 0.9 - 1.05 is acting as key support zone. Next key level to test is 1.7 - 1.82. Currently at 1.38 XCUR is moving slowly and steadily but nicely on daily chart. Key support at 5.4 - 5.8. Next key level to test is 7.6 - 8.1. Currently at 6.69 SUGP has made a move After hours. Currently at 8.40. It can test 9.75 - 10.30 zone again.
1 · Reply
stocksweets
stocksweets Dec. 5 at 12:47 AM
$AKAN and $VRAX
0 · Reply
stocksweets
stocksweets Dec. 5 at 12:43 AM
$VRAX
0 · Reply
stocksweets
stocksweets Dec. 5 at 12:06 AM
$VRAX and $AKAN
1 · Reply